


PHARMACEUTICAL 2023

Tonix Pharmaceuticals Holding Corp. Rank 96 of 446







RealRate

PHARMACEUTICAL 2023

## Tonix Pharmaceuticals Holding Corp. Rank 96 of 446

The relative strengths and weaknesses of Tonix Pharmaceuticals Holding Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tonix Pharmaceuticals Holding Corp. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Tonix Pharmaceuticals Holding Corp. is the variable Research and Development, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 202%, being 158% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	130,777
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,180
Liabilities, Non-Current	328
Other Assets	1,099
Other Compr. Net Income	-75
Other Expenses	0
Other Liabilities	0
Other Net Income	1,873
Other Revenues	0
Property and Equipment	93,814
Research and Development	81,876
Selling, General and Administrative Expense	30,215

Output Variable	Value in 1000 USD
Assets	225,690
Liabilities	18,508
Expenses	112,091
Revenues	0
Stockholders Equity	207,182
Net Income	-110,218
Comprehensive Net Income	-110,256
Economic Capital Ratio	202%

